Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

C F LeMaistre; M G Rosenblum; J M Reuben; D R Parkinson; C M Meneghetti; K Parker; J P Shaw; A B Deisseroth; T Woodworth

doi:10.1016/0140-6736(91)92788-4

Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

Lancet. 1991 May 11;337(8750):1124-5. doi: 10.1016/0140-6736(91)92788-4.

Authors

C F LeMaistre¹, M G Rosenblum, J M Reuben, D R Parkinson, C M Meneghetti, K Parker, J P Shaw, A B Deisseroth, T Woodworth

Affiliation

¹ Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.

PMID: 1674015
DOI: 10.1016/0140-6736(91)92788-4

Abstract

In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors--eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

Publication types

Case Reports

MeSH terms

Diphtheria Toxin / blood
Diphtheria Toxin / therapeutic use*
Drug Administration Schedule
Humans
Injections, Intravenous
Interleukin-2 / blood
Interleukin-2 / therapeutic use*
Leukemia, Lymphocytic, Chronic, B-Cell / blood
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukocyte Count / drug effects
Male
Middle Aged
Receptors, Interleukin-2 / drug effects*
Recombinant Fusion Proteins / blood
Recombinant Fusion Proteins / therapeutic use
T-Lymphocytes / drug effects

Substances

DAB(486)-interleukin 2
Diphtheria Toxin
Interleukin-2
Receptors, Interleukin-2
Recombinant Fusion Proteins